Chronic hepatitis B in a woman with chronic kidney disease
DOI: 10.32364/2587-6821-2020-4-11-710-713
Kh.G. Omarova1,2, V.V. Makashova1
1Central Research Institute of Epidemiology of the Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russian Federation
2LLC “SM–Clinic”, Moscow, Russian Federation
A 38-year-old woman was diagnosed with phase 2 chronic hepatitis B without delta-agent (HBeAg+) with a high biochemical and viral load and significant liver fibrosis (F2) five years after renal allotransplantation for a chronic kidney disease stage 5 resulting from a congenital urogenital abnormality (left renal hypoplasia). This woman was switched from lamivudine, the first-generation nucleoside analogue, that she received for 6 years, to entecavir (after a 4-year interval). However, the development of the resistance to entecavir forced to switch to tenofovir. A positive virological response was achieved as demonstrated by the lack of the isolation of hepatitis B virus (HBV) DNA one year after starting treatment. Yet, HBV is not detected. In addition, F2 fibrosis down-graded to F0 by the METAVIR score (as demonstrated by liver fibroelastometry). The woman is currently being followed-up.
Keywords: chronic hepatitis B, chronic kidney disease, renal allotransplantation, antiviral treatment, nucleoside analogues.
For citation: Omarova Kh.G., Makashova V.V. Chronic hepatitis B in a woman with chronic kidney disease. Russian Medical Inquiry. 2020;4(11):710–713. DOI: 10.32364/2587-6821-2020-4-11-710-713.
About the authors:
Khadizhat G. Omarova — Cand. of Sci. (Med.), researcher of the Central Research Institute of Epidemiology of the Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, 3A, Novogireevskaya str., Moscow, 111123, Russian Federation; gastroenterologist and hepatologist of LLC “SM–Clinic”, 42 build. 12, Volgogradskiy av., Moscow, 109316, Russian Federation; ORCID iD 0000-0002-9682-2230.
Vera V. Makashova — Doct. of Sci. (Med.), leading researcher of the Central Research Institute of Epidemiology of the
Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, 3A, Novogireevskaya str., Moscow, 111123, Russian Federation; ORCID iD 0000-0002-0982-3527.
Contact information: Khadizhat G. Omarova, e-mail: omarova71@inbox.ru. Financial Disclosure: no authors have a financial or property interest in any material or method mentioned. There is no conflict of interests. Received 06.09.2020, revised 29.09.2020, accepted 11.10.2020.
2. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. DOI: 10.1016/j.jhep.2017.03.021.
3. World Health Organization. Hepatitis B Fact Sheet. (Electronic resource.) URL: http://www.who.int/mediacentre/factsheets/fs204/en/. Access date: 28.08.2019.
4. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167–185. DOI: 10.1016/j.jhep.2012.02.010.
5. Schweitzer A., Horn J., Mikolajczyk R.T. et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–1555. DOI: 10.1016/S0140-6736 (15) 61412-X.
6. Vatazin A.V., Zulkarnaev A.B. Kidney transplantation as an optimal method of treating chronic kidney disease. Lechebnoye delo. 2013;3:47–52 (in Russ.).
7. Abdurakhmanov D.T. Chronic hepatitis B and D. M.: GEOTAR-Media; 2010 (in Russ)].
8. Kuo A., Gish R. Chronic hepatitis B infection. Clin Liver Dis. 2012;16(2):347–369. DOI: 10.1016/j.cld.2012.03.003.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать